Across TCGA pan-cancer cohorts, PDCD1LG2 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated PDCD1LG2 data layer compared with 24 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher PDCD1LG2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated PDCD1LG2 expression acts as an unfavorable survival marker, although some lineages such as LSCC and LUAD show a favorable association.

LSCC, LUAD, and GBM are the cancer types where PDCD1LG2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Quartile	All	0.896	0.477	.003	6	view →
LUAD	DFS	Tertile	All	0.925	0.241	.020	4	view →
GBM	DFS	Median	All	0.619	0.808	.022	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: PDCD1LG2 tumor-vs-normal RNA expression · all PDCD1LG2 data types